HMG-CoA reductase inhibition: Anti-inflammatory effects beyond lipid lowering?

European Journal of Preventive Cardiology

Volumn 10, Issue 3, 2003, Pages 169-179

  März, Winfried ^a   Köenig, Wolfgang ^b  

^a UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

atherosclerosis; cholesterol; coronary artery disease; HMG CoA reductase inhibitors; inflammation; pleiotropic effects

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; FLUINDOSTATIN; GELATINASE A; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; INTERLEUKIN 6 RECEPTOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; N(G) NITROARGININE METHYL ESTER; PRAVASTATIN; SIMVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MEVALONIC ACID; SELECTIN; SERUM AMYLOID A; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; IMMUNOMODULATION; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; PERIPHERAL VASCULAR DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECONDARY PREVENTION; STROKE; THROMBOCYTE AGGREGATION INHIBITION; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; DOWN REGULATION; INFLAMMATORY CELL; LEUKOCYTE; LIPID OXIDATION; LIVER; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; PLEIOTROPY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; HAPLORHINI; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MICE; RABBITS; RATS; VASCULITIS;

EID: 0038348392     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000073686.78271.6d     Document Type: Article

References (105)

1. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–1622.
2. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–1009.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Mac Farlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307.
6. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
7. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 287: 3215–3522.
8. Rosenson RS, Tangney CC. Anti-atherothrombotic properties of statins. JAMA 1998; 279: 1643–1650.
9. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–126.
10. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89: 2462–2478.
11. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844–2850.
12. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines, and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arteriscler Thromb 1991; 11: 1223–1230.
13. Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumour necrosis factor-alpha and interleukin-1 beta. Arterioscler Thromb Vasc Biol 1996; 16: 19–27.
14. Ridker PM, Hennekens CH, Riotman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88–92.
15. Rohde LE, Lee RT, Rivero J, Jamacochian M, Arroyo LH, Briggs W, et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1998; 18: 1765–1770.
16. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448–454.
17. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417–424.
18. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855–860.
19. Ferreiros ER, Boissonnet CP, Pizarro R, Merletti PF, Corrado G, Cagide A, et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 1999; 100: 1958–1963.
20. Morrow DA, Rifai N, Antman EM, Weiner DL, Mc Cabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A sub-study. J Am Coll Cardiol 1998; 31: 1460–1465.
21. de Winter RJ, Bholasingh R, Lijmer JG, Koster RW, Gorgels JP, Schouten Y. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q wave myocardial infarction. Cardiovasc Res 1999; 42: 240–245.
22. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144: 537–547.
23. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121–1127.
24. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 366: 729–732.
25. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low-grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 2000; 321: 199–204.
26. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731–733.
27. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843.
28. Roivainen M, Viik-Kajander M, Palosuo T, Toivanen P, Leinonen M, Saikku P, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000; 101: 252–257.
29. Köenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237–242.
30. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839–844.
31. Brown MS, Goldstein JL, Krieger M, Ho YK, Anderson RGW Reversible accumulation of cholesteryl esters in macrophages incubated with acetylated lipoproteins. J Cell Biol 1979; 82: 597.
32. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low-density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979; 76: 333–337.
33. Haberland ME, Fogelman AM, Edwards PA. Specificity of receptor-mediated recognition of malondialdehyde-modified low-density lipoproteins. Proc Natl Acad Sci USA 1982; 79: 1712–1716.
34. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low-density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low-density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984; 81: 3883–3887.
35. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999; 99: 993–998.
36. Tanner FC, Noll G, Boulanger CM, Lüscher TF. Oxidized low-density lipoproteins inhibit relaxations of porcine coronary arteries: Role of scavenger receptor and endothelium derived nitric oxide. Circulation 1991; 83: 2012–2020.
37. Galle J, Mülsch A, Busse R, Bassenge E. Effects of native and oxidized low density lipoproteins on formation and inactivation of endothelium derived relaxing factor. Arterioscl Thromb 1991; 11: 198–203.
38. Rajavashisth TB, Andalibi AS, Territo MC, Berliner JA, Navab M, Fogelman AM, et al. Induction of endothelial cell expression of granulocyte and macrophage colony stimulating factors by modified low-density lipoproteins. Nature 1990; 344: 254–257.
39. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, et al. Monocyte transmigration induced by modification of low density lipoprotein in co-cultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88: 2039–2046.
40. Drake TA, Hannani K, Fei H, Lavi S, Berliner JA. Minimally oxidized LDL induces tissue factor expression in cultured endothelial cells. Am J Pathol 1991; 138: 601–608.
41. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Up-regulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the apo E-deficient mouse. Arterioscler Thromb Vasc Biol 1998; 18: 842–851.
42. Sakai A, Kume N, Nishi E, Tanoue K, Miyasaka M, Kita T. P-selectin and vascular cell adhesion molecule-1 are focally expressed in aortas of hypercholesterolaemic rabbits before intimal accumulation of macrophages and T lymphocytes. Arterioscler Thromb Vasc Biol 1997; 17: 310–316.
43. Doi H, Kugiyama K, Oka H, Sugiyama S, Ogata N, Koide SI, et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 2000; 102: 670–676.
44. Mackness MI, Abbott C, Arrol S, Durrington PN. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993; 294: 829–834.
45. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152–154.
46. Christison JK, Rye KA, Stocker R. Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J Lipid Res 1995; 36: 2017–2026.
47. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high-density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 1998; 273: 6088–6095.
48. Nofer JR, Walter M, Kehrel B, Wierwille S, Tepel M, Seedorf U, et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-trisphosphate. Arterioscler Thromb Vasc Biol 1998; 18: 861–869.
49. Baumberger C, Ulevitch RJ, Dayer JM. Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology 1991; 59: 378–383.
50. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15: 1987–1994.
51. Dimayuga P, Zhu J, Oguchi S, Chyu KY, Xu XO, Yano J, et al. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Commun 1999; 264: 465–468.
52. Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR. High-density lipoproteins (HDL) interrupt the sphingosine kinase-signalling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999; 274: 33143–33147.
53. Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Phospholipid composition of reconstituted high-density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J Lipid Res 2000; 41: 1261–1267.
54. Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001; 103: 108–112.
55. Theilmeier G, De Geest B, Van Veldhoven PP, Stengel D, Michiels C, Lox M, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE mice. FASEB J 2000; 14: 2032–2039.
56. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, et al. C-reactive protein frequently co-localizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386–1392.
57. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094–2099.
58. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, et al. C-reactive protein, and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190: 1733–1740.
59. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: Binding of CRP to degraded, non-oxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348–2354.
60. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low-density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation 2001; 103: 1194–1197.
61. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000–1006.
62. West of Scotland Coronary Prevention Study Group Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study. Circulation 1998; 97: 1440–1445.
63. Ridker PM, Rifai N, Miles JS, et al. Lovastatin 20–40 mg/day lowers high sensitivity C-reactive protein levels in AFCAPS/TexCAPS. Circulation 2000; 102(Suppl.): II–833.
64. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–235.
65. Albert MA, Danielson E, Rifai N, Ridker P. Effect of statin therapy on C-reactive protein levels. JAMA 2001; 286: 64–70.
66. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933–1935.
67. Crisby M, Nordin-Fredrickson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Implications for plaque stabilization. Circulation 2001; 103: 926–933.
68. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, et al. The effect of pravastatin on acute rejection after kidney transplantation — a pilot study. Transplantation 1996; 61: 1469–1474.
69. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after transplantation. N Engl J Med 1995; 333: 621–627.
70. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. A four-year randomized trial. Circulation 1997; 96: 1398–1402.
71. de Bont N, Netea MG, Rovers C, Smilde T, Demacker PN, van der Meer JW, et al. LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolaemia and the effect of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 139: 147–152.
72. Rosenson RS, Tangney CC, Casey LC. Inhibition of pro-inflammatory cytokine production by pravastatin. Lancet 1999; 353: 983–984.
73. Strandberg TE, Vanhanen H, Tikkanen MJ. Associations between change in C-reactive protein and serum lipids during statin treatment. Ann Med 2000; 32: 579–583.
74. Bolibar I, von Eckardstein A, Assmann G, Thompson S. Short-term prognostic value of lipid measurements in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. Thromb Haemost 2000; 84: 955–960.
75. von Eckardstein A, Nofer JR, Assmann G. High-density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21: 13–27.
76. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolaemia. Circulation 2001; 103: 1191–1193.
77. Williams JK, Sukova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684–691.
78. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has anti-inflammatory and anti-atherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115–121.
79. Chakrabarti R, Engleman EG. Interrelationships between mevalonate metabolism and the mitogenic signalling pathway in T-lymphocyte proliferation. J Biol Chem 1991; 266: 12216–12222.
80. Cutts JL, Bankhurst AD. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin. Int J Immunopharmacol 1989; 11: 863–869.
81. Cutts JL, Bankhurst AD. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 1990; 145: 244–252.
82. Cutts JL, Scallen TJ, Watson J, Bankhurst AD. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989; 139: 550–557.
83. McPherson R, Tsoukas C, Baines MG, Vost A, Melino MR, Zupkis RV, et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993; 13: 439–444.
84. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399–1402.
85. Kreuzer J, Bader J, Jahn L. Chemotaxis of the monocyte line U937: Dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 1991; 90: 203–209.
86. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolaemia. J Am Coll Cardiol 1997; 30: 1212–1217.
87. Kallen J, Welzenbach K, Ramage P, Geyl D, Kriwacki R, Legge G, et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 1999; 292: 1–9.
88. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata D, Kallen J, Bruns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 6: 687–692.
89. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057–2064.
90. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000; 80: 1095–1100.
91. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolaemic rats. Arterioscler Thromb Vasc Biol 1996; 17: 1521–1526.
92. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999; 19: 2894–2900.
93. Lefer AM, Campbell B, Shin Y-K, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999; 100: 178–184.
94. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, et al. Atorvastatin reduces NF-kPB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253–261.
95. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997; 100: 2671–2679.
96. Kothe H, Dalhoff K, Rupp J, Muller A, Kreuzer J, Maass M, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000; 101: 1760–1763.
97. Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 1999; 269: 71–74.
98. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of mRNA levels for interleukin-1 β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARα) in primary endothelial cells. Life Sci 2000; 67: 863–876.
99. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kPB and AP-1. J Biol Chem 1999; 274: 32048–32054.
100. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkPBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000; 275: 36703–36707.
101. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357–362.
102. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425–430.
103. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isprenoid synthesis and cell growth. J Lipid Res 1980; 21: 505–517.
104. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997; 96: 4204–4210.
105. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462–466.